Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

IF 5.6 1区医学 Q1 Medicine

Breast Cancer Research Pub Date : 2025-06-13 DOI:10.1186/s13058-025-02058-x

Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt

{"title":"Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.","authors":"Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta, Peter Vermeulen, Luc Dirix, Adam David Dordevic, Evandro de Azambuja, Denis Larsimont, Marion Maetens, Elia Biganzoli, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Patrick Neven, Giuseppe Floris, Christine Desmedt","doi":"10.1186/s13058-025-02058-x","DOIUrl":null,"url":null,"abstract":"Purpose: The antibody-drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasive lobular carcinoma (ILC). Here, we aimed at analyzing the association of HER2-low with clinicopathological features and survival outcomes in patients with early-stage pure ILC.Methods: A multicentric retrospective cohort of patients diagnosed with stage I-III estrogen receptor positive (ER+) HER2 negative (HER2-) ILC between 01/01/2000 and 12/31/2020 was assembled. HER2- disease was categorized further by immunohistochemical (IHC) score into HER2 0, HER2 1+ and HER2 2+ following time appropriate ASCO/CAP guidelines from 2007 onward and by local guidelines prior to 2007. The association of HER2-low (HER2 1+ and 2+) with clinicopathological variables was assessed using multinomial logistic regression. Survival analyses were performed to evaluate the association of HER2-low with disease-free (DFS), distant recurrence-free (DRFS) and overall survival (OS).Results: The data of 2098 patients with ER+ HER2- ILC was collected of which 1103 (52.6%) had a HER2-low tumor. Of these 716 (34.1%) had an IHC score of HER2 1+ and 387 (18.4%) of HER2 2+. In multivariable analysis, both tumor size of ≥ 2cm (OR: 1.37; 95%CI 1.01 - 1.87; p-value 0.042) and multifocality (OR: 1.55; 95%CI 1.11 - 2.15; p-value 0.009) were associated with HER2-low. HER2-low was associated with worse DFS (HR: 1.32; 95%CI 1.06 - 1.66; p-value 0.015) and OS (HR: 1.42; 95%CI 1.12 - 1.81; p-value 0.004) as compared to HER2 0. No association of HER2-low with DRFS was observed.Conclusions: HER2-low is present in more than half of the patients with early ER+ HER2- pure ILCs and is associated with larger tumor size and multifocality. HER2-low is associated with a worse DFS and OS as compared to HER2 0.","PeriodicalId":49227,"journal":{"name":"Breast Cancer Research","volume":"27 1","pages":"106"},"PeriodicalIF":5.6000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166569/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13058-025-02058-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The antibody-drug conjugate trastuzumab deruxtecan has proven to be not only efficient in patients with HER2+ breast cancers (BC), but also in those patients with so-called HER2-low BC. HER2-low tumors are well described in the general BC population, but not in patients with invasive lobular carcinoma (ILC). Here, we aimed at analyzing the association of HER2-low with clinicopathological features and survival outcomes in patients with early-stage pure ILC.

Methods: A multicentric retrospective cohort of patients diagnosed with stage I-III estrogen receptor positive (ER+) HER2 negative (HER2-) ILC between 01/01/2000 and 12/31/2020 was assembled. HER2- disease was categorized further by immunohistochemical (IHC) score into HER2 0, HER2 1+ and HER2 2+ following time appropriate ASCO/CAP guidelines from 2007 onward and by local guidelines prior to 2007. The association of HER2-low (HER2 1+ and 2+) with clinicopathological variables was assessed using multinomial logistic regression. Survival analyses were performed to evaluate the association of HER2-low with disease-free (DFS), distant recurrence-free (DRFS) and overall survival (OS).

Results: The data of 2098 patients with ER+ HER2- ILC was collected of which 1103 (52.6%) had a HER2-low tumor. Of these 716 (34.1%) had an IHC score of HER2 1+ and 387 (18.4%) of HER2 2+. In multivariable analysis, both tumor size of ≥ 2cm (OR: 1.37; 95%CI 1.01 - 1.87; p-value 0.042) and multifocality (OR: 1.55; 95%CI 1.11 - 2.15; p-value 0.009) were associated with HER2-low. HER2-low was associated with worse DFS (HR: 1.32; 95%CI 1.06 - 1.66; p-value 0.015) and OS (HR: 1.42; 95%CI 1.12 - 1.81; p-value 0.004) as compared to HER2 0. No association of HER2-low with DRFS was observed.

Conclusions: HER2-low is present in more than half of the patients with early ER+ HER2- pure ILCs and is associated with larger tumor size and multifocality. HER2-low is associated with a worse DFS and OS as compared to HER2 0.

Abstract Image

查看原文本刊更多论文

早期浸润性小叶性乳腺癌患者her2 -低水平与临床病理特征的关系：一项国际多中心研究

目的：抗体-药物偶联曲妥珠单抗德鲁西替康已被证明不仅对HER2阳性乳腺癌（BC）患者有效，而且对那些所谓的HER2低BC患者有效。her2低肿瘤在一般BC人群中有很好的描述，但在浸润性小叶癌（ILC）患者中没有。在这里，我们的目的是分析her2低与早期纯ILC患者的临床病理特征和生存结局的关系。方法：对2000年1月1日至2020年12月31日诊断为I-III期雌激素受体阳性（ER+） HER2阴性（HER2-） ILC的患者进行多中心回顾性队列研究。HER2-疾病根据免疫组织化学（IHC）评分进一步分为HER2 0、HER2 1+和HER2 +，遵循ASCO/CAP 2007年之后的适当时间指南和2007年之前的当地指南。使用多项逻辑回归评估HER2-低（HER2 1+和2+）与临床病理变量的关系。进行生存分析以评估HER2-low与无病（DFS）、无远处复发（DRFS）和总生存（OS）的关系。结果：共收集到2098例ER+ HER2- ILC患者资料，其中1103例（52.6%）为HER2低肿瘤。其中716例（34.1%）的IHC评分为HER2 1+， 387例（18.4%）的HER2 2+。在多变量分析中，肿瘤大小≥2cm (OR: 1.37；95%ci 1.01 - 1.87；p值0.042)和多焦点性(OR: 1.55；95%ci 1.11 - 2.15；p值为0.009)与her2低相关。her2低与较差的DFS相关(HR: 1.32；95%ci 1.06 - 1.66；p值0.015)和OS (HR: 1.42；95%ci 1.12 - 1.81；p值为0.004)。没有观察到HER2-low与DRFS的关联。结论：HER2低存在于超过一半的早期ER+ HER2纯ILCs患者中，并且与较大的肿瘤大小和多灶性有关。与HER2相比，HER2低与更差的DFS和OS相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Research ONCOLOGY-

CiteScore

12.00

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Breast Cancer Research, an international, peer-reviewed online journal, publishes original research, reviews, editorials, and reports. It features open-access research articles of exceptional interest across all areas of biology and medicine relevant to breast cancer. This includes normal mammary gland biology, with a special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition to basic research, the journal covers preclinical, translational, and clinical studies with a biological basis, including Phase I and Phase II trials.